Previous 10 | Next 10 |
CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin HOUSTON , Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the developme...
The FDA signs off CNS Pharmaceuticals' ([[CNSP]] +9.6%) Investigational New Drug application for berubicin, for the treatment of Glioblastoma Multiforme, most aggressive form of brain cancer.The Company will initiate its trial during Q1 of 2021 to investigate the efficacy of Berubicin in adul...
Palm Beach, FL – December 17, 2020 – Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial...
CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin HOUSTON , Dec. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc . (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializi...
LOS ANGELES, Dec. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, chairman and CEO of CNS Pharmaceuticals Inc...
HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces ...
CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting PR Newswire HOUSTON, Nov. 19, 2020 HOUSTON , Nov. 19, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a bioph...
CNS Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium PR Newswire HOUSTON, Nov. 18, 2020 HOUSTON , Nov. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializ...
Palm Beach, FL – November 17, 2020 – With the increasing prevalence of brain cancer, rising aging population, and growing incidences of cancer via chemical exposure, the demand of diagnosis and treatment of brain tumors is steadily increasing. The diagnosis, treatments, therap...
CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin Expects to initiate Phase 2 trial during the first quarter of 2021 PR Newswire HOUSTON, Nov. 17, 2020 HOUSTON , Nov. 17, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc....
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its ab...
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...